Apyx Medical (NASDAQ:APYX) Releases Earnings Results, Misses Estimates By $0.02 EPS

Apyx Medical (NASDAQ:APYX – Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02), MarketWatch Earnings reports. Apyx Medical had a negative return on equity of 26.79% and a negative net margin of 31.27%. During the same period in the prior year, the company earned ($0.14) earnings per share. Apyx Medical updated its FY 2022 guidance to EPS.

NASDAQ APYX opened at $3.65 on Friday. The business’s fifty day moving average is $5.76 and its 200 day moving average is $10.14. Apyx Medical has a fifty-two week low of $3.01 and a fifty-two week high of $17.50.

Several hedge funds and other institutional investors have recently bought and sold shares of APYX. Captrust Financial Advisors lifted its position in shares of Apyx Medical by 69.0% during the 3rd quarter. Captrust Financial Advisors now owns 2,450 shares of the company’s stock valued at $34,000 after buying an additional 1,000 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Apyx Medical by 289.8% in the third quarter. BNP Paribas Arbitrage SA now owns 5,445 shares of the company’s stock worth $75,000 after purchasing an additional 4,048 shares during the period. Royal Bank of Canada raised its position in shares of Apyx Medical by 155.6% during the 3rd quarter. Royal Bank of Canada now owns 5,459 shares of the company’s stock valued at $76,000 after purchasing an additional 3,323 shares during the period. Citigroup Inc. lifted its stake in shares of Apyx Medical by 127.3% during the 4th quarter. Citigroup Inc. now owns 7,929 shares of the company’s stock valued at $102,000 after buying an additional 4,440 shares in the last quarter. Finally, Invesco Ltd. bought a new position in Apyx Medical in the 2nd quarter worth $117,000. 61.03% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on the stock. Colliers Securities reissued a “buy” rating on shares of Apyx Medical in a report on Tuesday, March 22nd. Piper Sandler lowered their price target on Apyx Medical from $12.00 to $6.00 in a report on Thursday. Finally, Zacks Investment Research lowered Apyx Medical from a “hold” rating to a “sell” rating in a report on Friday.

About Apyx Medical (Get Rating)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.

Featured Stories